Over the past two decades, the management landscape of clinically localized prostate cancer (PCa) has undergone a significant transformation, shifting away partly from conventional radical approaches such as radical prostatectomy (RP) and radiation therapy (RT) to active surveillance (AS) and focal therapy (FT) [1,2]. These radical approaches have been proved to have good oncological efficacy; however, these are often accompanied by complications and a decrease in functional outcomes, resulting in worsening in quality of life (QOL) [3]. This arguably renders these approaches inappropriate for universal application in all grades of PCa disease. Consequently, there is a need for an alternative approach, namely, image-guided focal ablation (FT) that not only ensures effective oncological control, but also minimizes functional detriments associated with treatment [[4], [5], [6], [7]].

Initially utilized as an alternative to AS for low-risk PCa with progressive disease, FT has now been upgraded as a treatment option for intermediate-risk PCa in those who benefit from curative therapy [8,9]. In recent years, multiple studies have demonstrated good early- to mid-term (2–5 yr) oncological outcomes following FT of PCa [[4], [5], [6], [7]]. However, long-term (10 yr) oncological outcomes were lacking in the literature. In this study, we report the long-term oncological and functional outcomes of partial gland cryoablation (herein referred to as “FT”) in patients with nonmetastatic localized PCa.